These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 8678492)
1. [Treatment for hormone-refractory or relapsing prostatic cancer]. Hirao Y; Ozono S; Okajima E Gan To Kagaku Ryoho; 1996 Mar; 23(4):418-26. PubMed ID: 8678492 [TBL] [Abstract][Full Text] [Related]
2. [Chemotherapy of prostatic cancer]. Hirao Y; Kubota K; Yoshie T; Tabata S; Samma S; Ozono S; Okajima E; Sasaki K; Yoshikawa M; Tsumatani K Hinyokika Kiyo; 1991 Aug; 37(8):817-24. PubMed ID: 1720273 [TBL] [Abstract][Full Text] [Related]
3. [Clinical evaluation of chemotherapy in urologic cancer]. Miki T; Kuroda M; Kotake T Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1349-57. PubMed ID: 2471457 [TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
5. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
6. [Response to chemotherapy in endocrine therapy-relapsed and -resistant prostate cancer]. Akimoto S; Akakura K; Masai M; Shimazaki J Hinyokika Kiyo; 1991 Jan; 37(1):31-7. PubMed ID: 1707216 [TBL] [Abstract][Full Text] [Related]
7. [Cyclophosphamide, adriamycin and cisplatinum combination chemotherapy for advanced urothelial and prostatic carcinoma]. Tsukamoto T; Tanoguchi H; Nakazono M; Murai M; Tachibana M; Deguchi N; Baba S; Hata M; Jitsukawa S; Tazaki H Gan To Kagaku Ryoho; 1987 Dec; 14(12):3259-64. PubMed ID: 3688891 [TBL] [Abstract][Full Text] [Related]
8. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727 [TBL] [Abstract][Full Text] [Related]
9. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S; Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326 [TBL] [Abstract][Full Text] [Related]
10. [Preliminary report on the effect of etoposide or etoposide and CDDP on recurrent prostate cancer]. Suzuki K; Nakamura T; Kato N; Kurita M; Nakazawa Y; Suzuki T; Imai K; Yamanaka H Hinyokika Kiyo; 1991 Nov; 37(11):1499-503. PubMed ID: 1767772 [TBL] [Abstract][Full Text] [Related]
11. [The role of etoposide therapy in urogenital cancer]. Kawai K; Akaza H Gan To Kagaku Ryoho; 1996 Dec; 23(14):1929-35. PubMed ID: 8978800 [TBL] [Abstract][Full Text] [Related]
12. [Induction therapy with CDDP and ADM for stage D prostatic cancer and its clinical response]. Yushita Y; Sakai H; Nomata K; Suzu H; Minami Y; Ogawa S; Yamashita S; Kanetake H; Saito Y Hinyokika Kiyo; 1990 Dec; 36(12):1415-21. PubMed ID: 2075879 [TBL] [Abstract][Full Text] [Related]
13. [New combination chemotherapy in refractory rhabdomyosarcoma of the prostate: a case report and review of the literature]. Takeuchi T; Komeda H; Oguchi K; Ishihara S; Iwata H; Kanematsu M; Kuriyama M; Ban Y; Tanaka T Hinyokika Kiyo; 1987 Nov; 33(11):1899-905. PubMed ID: 2451411 [TBL] [Abstract][Full Text] [Related]
14. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530 [TBL] [Abstract][Full Text] [Related]
15. [Intra-arterial chemotherapy of relapsed and hormone-resistant prostate cancer using reservoir system]. Ueno K; Shinoda I; Takahashi Y; Kawamoto S; Yamamoto N; Kuriyama M; Kawada Y; Nagatani Y; Takeuchi T; Sakai S Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 2):1783-7. PubMed ID: 2389965 [TBL] [Abstract][Full Text] [Related]
16. Management of hormone refractory prostate cancer: current standards and future prospects. Oh WK; Kantoff PW J Urol; 1998 Oct; 160(4):1220-9. PubMed ID: 9751323 [TBL] [Abstract][Full Text] [Related]
17. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma. Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492 [TBL] [Abstract][Full Text] [Related]
18. [Combination chemotherapy with ifosfamide, 5-fluorouracil, cisplatin for stage D2 prostatic cancer]. Takeuchi S; Fukui I; Higashi Y; Andoh M; Kihara K; Kitahara S; Horiuchi S; Oshima H Hinyokika Kiyo; 1989 Sep; 35(9):1513-7. PubMed ID: 2816618 [TBL] [Abstract][Full Text] [Related]
19. New options for the treatment of advanced ovarian cancer. Dunton CJ Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739 [TBL] [Abstract][Full Text] [Related]
20. [Combination chemotherapy with ifosfamide (or cyclophosphamide), adriamycin, cis-platinum and peplomycin (IAPP) for hormonally resistant metastatic prostatic cancer]. Maeda O; Saiki S; Kinouchi T; Kuroda M; Miki T; Usami M; Kotake T Hinyokika Kiyo; 1991 Dec; 37(12):1657-62. PubMed ID: 1723841 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]